Multiple Myeloma Minimal Residual Disease

Area of Science:

• Hematology
• Oncology
• Clinical Diagnostics

Background:

• Minimal residual disease (MRD) assessment is standard for curable neoplasms.
• Multiple myeloma (MM) treatment is improving, increasing the need for sensitive monitoring techniques.
• Conventional methods are suboptimal for evaluating new, highly effective MM therapies.

Purpose of the Study:

• To review remission depth criteria and their clinical significance in MM.
• To discuss the prognostic value and characteristics of MRD detection techniques in MM.
• To highlight the need for standardized, sensitive MRD assays in MM clinical trials.

Main Methods:

• Review of existing literature on MRD detection in multiple myeloma.
• Analysis of immunophenotypic, molecular, and imaging techniques for MRD assessment.
• Evaluation of remission criteria and their clinical significance.

Main Results:

• New MM therapies necessitate sensitive MRD monitoring.
• MRD may be a more potent survival biomarker than complete remission (CR).
• Understanding the pros and cons of different MRD techniques is essential.

Conclusions:

• Highly sensitive, cost-effective, and standardized MRD techniques should be incorporated into MM clinical trials.
• MRD assessment can guide therapeutic decisions and improve patient outcomes.
• The role of MRD in MM requires further investigation and standardization.